Fundraising Fox

A2 Biotherapeutics

Founded 2018 · 122 employees on LinkedIn · 2 known investors

A2 Biotherapeutics develops cell therapy technology using the Tmod platform, which applies quantitative drug discovery methods to treat cancer patients.

BiotechDeep TechDigital HealthHealthtechMedical Devices

Founders & leadership

JRJim Robinson
Jim RobinsoninCEO

Investors · 2

The Column GroupSan Francisco · $30M
Samsara BioCapitalreportedPalo Alto

Funding

SEC filings, press & company announcements

$80M disclosed across 1 of 3 rounds · 2022–2025

Source: company announcements and press reports — follow each round's link for the claim.

In the news

A2 Biotherapeutics: $80 Million (Series C) Raised For Advancing Clinical Development Of Precision Cell Therapiespulse2.com · Jan 2025A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours - Pharmaceutical Technologypharmaceutical-technology.com · Jan 2025A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of Its Precision Cell Therapies Using Its Proprietary Tmod™ Technology Platformbusinesswire.com · Jan 2025A2 Biotherapeutics Raises $80M Series C Fundingfinsmes.com · Jan 2025Scoop: A2 Biotherapeutics raises $62M for solid tumor cell therapiesendpoints.news · Dec 2022A2 Biotherapeutics Closes $71.5M Series B Funding - FinSMEsfinsmes.com · Oct 2020

Frequently asked questions

What does A2 Biotherapeutics do?
A2 Biotherapeutics develops cell therapy technology using the Tmod platform, which applies quantitative drug discovery methods to treat cancer patients.
Who are A2 Biotherapeutics's investors?
A2 Biotherapeutics's investors include The Column Group, Samsara BioCapital.
How much funding has A2 Biotherapeutics raised?
A2 Biotherapeutics has disclosed $80M raised across 1 of its 3 known rounds.